- ISIN
- US12674W1099
- CUSIP
- 12674W109
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Oct 25, 2019
Highlights
- Market Cap
- $436.99M
- Enterprise Value
- $369.92M
- EPS (TTM)
- -$1.66
- Gross Profit (TTM)
- $148.00K
- EBITDA (TTM)
- -$181.04M
- Year Range
- $1.26 - $4.23
- Target Price
- $16.33
- ROA (TTM)
- -118.42%
- ROE (TTM)
- -169.82%
- Avg. Volume (1M)
- 4M
- Avg. Volume Value (1M)
- $11.48M
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
CABA Performance Chart
Cabaletta Bio, Inc. (CABA) is up 22.4% since the beginning of the year. At $3 per share, CABA is trading 36.6% below its 52-week high of $4. Investors who bought $1,000 worth of CABA shares 5 years ago would now be looking at an investment worth $359.
Loading charts...
Compare this symbol against anything
Returns By Period
Cabaletta Bio, Inc. (CABA) has returned 22.37% so far this year and 86.11% over the past 12 months.
Cabaletta Bio, Inc.
- 1D
- -1.47%
- 1M
- -15.99%
- 6M
- 4.28%
- YTD
- 22.37%
- 1Y
- 86.11%
- 3Y*
- -40.35%
- 5Y*
- -18.51%
- 10Y*
- —
- ALL TIME*
- -16.39%
Benchmark (S&P 500 Index)
- 1D
- 0.70%
- 1M
- 0.09%
- 6M
- 7.94%
- YTD
- 9.41%
- 1Y
- 20.07%
- 3Y*
- 17.84%
- 5Y*
- 11.25%
- 10Y*
- 13.26%
- ALL TIME*
- 8.09%
CABA Monthly Returns History
Based on dividend-adjusted daily data since Oct 25, 2019, CABA's average daily return is +0.18%, while the average monthly return is +3.54%. At this rate, an investment would double in approximately 1.7 years.
Historically, 48% of months were positive and 52% were negative. The best month was Nov 2022 with a return of +165.1%, while the worst month was Dec 2021 at -67.3%. The longest winning streak lasted 4 consecutive months, and the longest losing streak was 8 months.
On a daily basis, CABA closed higher 46% of trading days. The best single day was Oct 20, 2022 with a return of +50.8%, while the worst single day was Dec 14, 2021 at -73.1%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 17.35% | 29.18% | -18.98% | 11.15% | 26.42% | -17.72% | -13.83% | 22.37% | |||||
| 2025 | 5.29% | -24.48% | -23.27% | -4.69% | 41.67% | -18.72% | 0.00% | -4.61% | 61.38% | 54.27% | -28.81% | -14.79% | -3.52% |
| 2024 | -9.78% | 11.72% | -25.44% | -37.60% | -4.27% | -26.59% | -5.08% | -20.70% | -16.16% | -24.79% | 7.61% | -40.58% | -90.00% |
| 2023 | 31.78% | -27.48% | -6.45% | 25.51% | -2.79% | 27.95% | 5.50% | 3.96% | 7.49% | -6.31% | 12.55% | 41.43% | 145.41% |
| 2022 | -20.32% | -28.48% | -6.02% | -32.02% | -7.25% | -17.19% | 11.32% | -19.08% | -31.92% | 159.96% | 165.09% | 106.47% | 144.06% |
| 2021 | 4.41% | -16.58% | 2.12% | 0.27% | 1.89% | -24.16% | -13.26% | 36.46% | 19.45% | 12.42% | -15.29% | -67.27% | -69.63% |
Benchmark Metrics
Cabaletta Bio, Inc. has an annualized alpha of 28.90%, beta of 1.21, and R2 of 0.05 versus S&P 500 Index. Calculated based on daily prices since October 25, 2019.
- This stock participated in 215.04% of S&P 500 Index downside but only 154.11% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.05 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 28.90%
- Beta
- 1.21
- R²
- 0.05
- Upside Capture
- 154.11%
- Downside Capture
- 215.04%
Return for Risk
Risk / Return Rank
CABA ranks 75 for risk / return — above 75% of stocks peers on PortfoliosLab. Its historical combined result is above most peers.
Risk / Return Metrics
The table below present risk-adjusted performance metrics for Cabaletta Bio, Inc. (CABA) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| CABA | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.68 | ||
| Sortino ratioReturn per unit of downside risk | 0.00 | ||
| Omega ratioGain probability vs. loss probability | 1.22 | 1.25 | -0.03 |
| Calmar ratioReturn relative to maximum drawdown | 1.76 | 2.00 | -0.24 |
| Martin ratioReturn relative to average drawdown | 3.28 | 8.49 | -5.21 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Cabaletta Bio, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Cabaletta Bio, Inc. was 96.63%, occurring on Sep 23, 2022. Recovery took 294 trading sessions.
The current Cabaletta Bio, Inc. drawdown is 89.44%.
Drawdown | Fall | Recovery | Underwater | Related event |
|---|---|---|---|---|
-96.63%Sep 2022 | 2y 7mo | 1y 2mo | 3y 9moJan 2020 - Nov 2023 | Bear market2022 |
-95.90%Apr 2025 | 1y 1mo | — | 2y 5moFeb 2024 - now | 2025 selloff2025 |
-55.51%Dec 2019 | 22d | 1mo 18d | 2mo 10dNov 2019 - Jan 2020 | — |
-26.79%Nov 2023 | 1d | 15d | 15dNov 2023 - Dec 2023 | — |
-19.64%Jan 2024 | 10d | 20d | 1moJan 2024 - Feb 2024 | — |
Drawdown Indicators
| CABA | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -96.63% | -56.78% | -39.85% |
Max Drawdown (1Y)Largest decline over 1 year | -43.49% | -9.10% | -34.39% |
Max Drawdown (3Y)Largest decline over 3 years | -95.90% | -18.90% | -77.00% |
Max Drawdown (5Y)Largest decline over 5 years | -95.90% | -25.43% | -70.47% |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -89.44% | -1.58% | -87.86% |
Average DrawdownAverage peak-to-trough decline | -60.30% | -10.70% | -49.60% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 23.32% | 2.14% | +21.18% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Cabaletta Bio, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Cabaletta Bio, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for CABA in comparison with other companies in the Biotechnology industry. Currently, CABA has a P/B value of 2.9. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with CABA
Add Cabaletta Bio, Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with CABA